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BACKGROUND, AIM & OBJECTIVES:  
 
Using Patient Reported Outcome Measures (PROMs) cancer care can improve patient overall survival (1). Tools that assess quality of life 
(QoL) can aid clinicians to more informed treatment decisions. Treatment impact on QoL is not systematically recorded as part of the clinic 
appointment pathway. The Cancer Medicines Outcomes Programme (CMOP) aims to test the feasibility of collecting PROMs in-clinic.  To 
maximise the impact of PROMs for patients, it is recommended to develop an electronic, integrated solution, through engaging 
stakeholders in identifying which outcomes to measure using validated resources and in the wider strategy (2). This study aims to: engage 
with prostate cancer clinicians and patients / carers using consensus methods to understand which aspects of QoL are important in relation 
to treatment impact on QoL; and map these areas to validated PROMs tools to select the best fit.  
METHODS: 
 
PROMs tools were identified (n=30) and the QoL areas 
covered were put into a framework of domains (n=9) and 
domain elements (n=70).  
 
CLINICIANS in the West of Scotland took part in online 
questionnaires (3 stage eDelphi), ranking which QoL 
domains / elements were most important. Important 
domains / elements were mapped to the n=30 PROMs 
tools and a selection of tools reflective of clinician 
priorities formed eDelphi 3.  
 
PATIENTS/CARERS from prostate cancer support groups in 
Glasgow (n=2) took part in focus groups (Nominal Group 
Technique (NGTs)). Patients / carers of those attending 
prostate cancer clinics (n=2) were invited to complete 
paper questionnaire version of the NGT. All used a Likert-
type scale to rate the importance of each domain 
element. 
 
Data were respectively analysed. Cut-off points for 
importance were calculated. Important elements were 
mapped back to the n=30 PROMs tools utilising NVivo.  
RESULTS: 
 
N=146 prostate cancer clinicians in the West of Scotland 
were invited to participate. N=21 completed eDelphi 1 and 2, 
and n=13 eDelphi 3. N=30 patients / carers took part in NGTs 
and n=44 completed clinic questionnaires (Figure 1). The 
NCCN Distress Thermometer & Problems List, in combination 









Figure 1: Data Collection Methodology, Participant Numbers and Results 
Figure 2: Domain Elements important to clinicians, patients/carers and both groups 
NEXT STEPS & CONCLUSIONS: 
 
Next steps include: engaging with clinicians and patients / 
carers to design a patient app and a clinician dashboard; and 
sampling from prostate and other cancer areas to cover a 
wider demographic. In preparation for small-scale testing, 
collaboration with NHS is required to embed the pilot 
dashboard within clinical systems used by clinicians to 
facilitate ease of use and overall value.  
 
This work demonstrates engagement with stakeholders in 
the exploration of the important areas of QoL when 
discussing treatment impact in prostate cancer. It reflects 
the importance clinicians and the wider research community 
place on the impact of PROMs in the patient treatment 
pathway and provides further evidence for future work.  
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